Business Context and Reporting Period
NanoViricides, Inc. (NNVC) filed a Current Report on Form 8-K dated August 29, 2023. The company, incorporated in Delaware and listed on the NYSE American, is an emerging growth company. The filing reports the entry into a definitive material agreement with TheraCour Pharma, Inc., a related party entity owned approximately 90% by NanoViricides' founder, President, and Chairman, Dr. Anil Diwan.
Key Financial Metrics and Obligations
This filing does not report revenue, profit, cash flow, or general liquidity metrics. It specifically details a new financial obligation:
- Principal Amount: $1,500,000
- Instrument: Convertible Promissory Note
- Interest Rate: 12% per annum
- Maturity Date: January 19, 2025
- Conversion Feature: Convertible at TheraCour's option into Series A Convertible Preferred Stock.
Material Changes and Transaction Details
The transaction stems from a Licensing Agreement dated September 7, 2021. TheraCour achieved a milestone regarding the "Initiation of Phase 1 Clinical Trials or Equivalent" within three months of regulatory approval. This triggered a cash milestone payment obligation of $1,500,000. Instead of a cash payment, the parties executed a Deferred Expense Exchange Agreement effective July 19, 2023, converting the obligation into the Convertible Promissory Note described above. Dr. Diwan recused himself from Board voting on this matter.
Guidance, Risks, and Contingencies
The filing does not provide forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosures inherent in the agreement. The primary contingency is the potential conversion of the $1,500,000 debt into equity (Series A Shares), which would dilute existing shareholders depending on the conversion price specified in the Note.
Investor Verification Checklist
- Verify the specific conversion price and terms for the Series A Convertible Preferred Stock in Exhibit 10.3.
- Confirm the impact of the 12% interest accrual on future interest expense.
- Review the related party nature of the transaction given Dr. Diwan's 90% ownership of TheraCour.
- Assess the company's current cash position to determine if the $1.5 million principal will be paid in cash at maturity or converted to equity.